Pharmaceutical Technology's In the Lab eNewsletter
Dublin, Ireland-based biopharmaceutical company Allergan will establish an R&D presence in Cambridge, MA.
Dublin, Ireland-based biopharmaceutical company Allergan announced on Jan. 7, 2019 that it will establish an R&D presence in the Kendall Square section of Cambridge, MA.
The site will be led by Don Frail, PhD, senior vice-president of Research and External Scientific Innovation and Non-Clinical and Translational Sciences. The company states that its R&D model, Open Science, incorporates partnering with biotech companies, academia, and other pharmaceutical companies to broaden its pipeline. The Cambridge site joins the company’s other US-based R&D sites in Madison, NJ, and San Francisco, CA.
"One of the driving sources of innovation today comes from smaller biotechnology and pharma companies. Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and startups in the area," said David Nicholson, executive vice-president and chief R&D officer, in a company press release. "I am confident that our new location in Cambridge will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines."
The company focuses on developing, manufacturing, and commercializing pharmaceutical, device, biologic, surgical, and regenerative medicine products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutics.
Source: Allergan
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.